

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Oncology Pharma, Inc.

One Sansome Street
Suite 3500
San Francisco, CA

(415) 869-1038
www.oncology-pharma.com
info@oncology-pharma.com
2834

Quarterly Report

For the period ending December 31,2022 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

38,563,216 as of December 31,2022

33,763,216 as of March 31,2022

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

¹ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Oncology Pharma, Inc., Nevada corporation, Active
SourcingLink.net.Inc., Nevada corporation until 4/2019
QCS.net Corporation, Delaware corporation until 7/1/1999
Parkway Capital Corporation, Colorado until 6/1994

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada, Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

One Sansome Street
Suite 3500
San Francisco, CA 94104

The address(es) of the issuer's principal place of business:

X Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Olde Monmouth Stock Transfer Co. Inc.
Phone: (732) 872-2727
Email: matt@oldemonmouth.com
Address: 200 Memorial Pkwy, Atlantic Highlands, NJ 07716

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	ONPH	
Exact title and class of securities outstanding:	Common	
CUSIP:	68235J201	
Par or stated value:	\$0.001	
Total shares authorized:	900,000,000	<u>as of date: December 31, 2022</u>
Total shares outstanding:	38,563,216	<u>as of date: December 31, 2022</u>
Total number of shareholders of record:	208	<u>as of date: December 31, 2022</u>

All additional class(es) of publicly quoted or traded securities (if any):

Trading symbol:	_____	
Exact title and class of securities outstanding:	_____	
CUSIP:	_____	
Par or stated value:	_____	
Total shares authorized:	_____	<u>as of date: _____</u>
Total shares outstanding:	_____	<u>as of date: _____</u>
Total number of shareholders of record:	_____	<u>as of date: _____</u>

Trading symbol:	_____	
Exact title and class of securities outstanding:	_____	
CUSIP:	_____	
Par or stated value:	_____	
Total shares authorized:	_____	<u>as of date: _____</u>
Total shares outstanding:	_____	<u>as of date: _____</u>
Total number of shareholders of record:	_____	<u>as of date: _____</u>

Other classes of authorized or outstanding equity securities:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	Preferred Series A	
CUSIP (if applicable):	_____	
Par or stated value:	\$0.001 par value	
Total shares authorized:	100,000,000	<u>as of date: December 31, 2022</u>
Total shares outstanding (if applicable):	1 share	<u>as of date: December 31, 2022</u>
Total number of shareholders of record (if applicable):	1	<u>as of date: December 31, 2022</u>

Exact title and class of the security:	_____
CUSIP (if applicable):	_____

Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding (if applicable): _____ as of date: _____
Total number of shareholders of record
(if applicable): _____ as of date: _____

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Pro rata dividend and voting rights. No preemption rights.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

No dividend preferential rights, 51% of votes for shareholder voting power, no conversion rights, liquidation at par value.

3. Describe any other material rights of common or preferred stockholders.

None _____

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None _____

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End:			*Right-click the rows below and select "Insert" to add rows as needed.						
Opening Balance									
Date <u>3/31/2021</u>			Common:						
<u>27,338,716</u>			Preferred: <u>1,000</u>						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>4/12/2021</u>	<u>New</u>	<u>50,000</u>	<u>Common</u>	<u>\$28</u>	<u>No</u>	<u>Regen Biopharma, Inc. (Control person: David Koos</u>	<u>License fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/5/2021</u>	<u>New</u>	<u>800,000</u>	<u>Common</u>	<u>\$37</u>	<u>Yes</u>	<u>Life Sciences Journeys, Inc. (Control person: Kevin Dills</u>	<u>Debt conversion</u>	<u>Unrestricted</u>	<u>Rule 144</u>
<u>8/4/2021</u>	<u>New</u>	<u>1,600,000</u>	<u>Common</u>	<u>\$21</u>	<u>Yes</u>	<u>Bright Star International, Inc. (Control person: Kevin Dills</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>Rule 144</u>
<u>8/6/2021</u>	<u>Cancellation</u>	<u>(25,000)</u>	<u>Common</u>	<u>\$2</u>	<u>No</u>	<u>Kalos Therapeutics Inc. (Control person: George Kohlberg)</u>	<u>Legal Settlement</u>	<u>Cancellation</u>	<u>Rule 144</u>
<u>9/22/2021</u>	<u>New</u>	<u>1,800,000</u>	<u>Common</u>	<u>\$12</u>	<u>Yes</u>	<u>Bright Star International, Inc. (Control person: Kevin Dills)</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>Rule 144</u>
<u>11/17/2021</u>	<u>New</u>	<u>2,200,000</u>	<u>Common</u>	<u>\$8</u>	<u>Yes</u>	<u>Bright Star International, Inc. (Control person: Kevin Dills)</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>Rule 144</u>

<u>7/14/2022</u>	<u>New</u>	<u>2,000,000</u>	<u>Common</u>	<u>\$1</u>	<u>Yes</u>	<u>Bright Star International, Inc. (Control person: Kevin Dills)</u>	<u>Debt conversion</u>	<u>Unrestricted</u>	<u>Rule 144</u>
<u>8/25/2022</u>	<u>New</u>	<u>2,200,000</u>	<u>Common</u>	<u>\$1</u>	<u>Yes</u>	<u>Bright Star International, Inc. (Control person: Kevin Dills)</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>Rule 144</u>
<u>10/20/2022</u>	<u>New</u>	<u>600,000</u>	<u>Common</u>	<u>\$.39</u>	<u>Yes</u>	<u>Bright Star International, Inc. (Control person: Kevin Dills)</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>Rule 144</u>
Shares Outstanding on Date of This Report:									
<u>Ending Balance</u>		<u>Ending</u>							
<u>Balance:</u>									
Date <u>12/31/2022</u>	Common:								
<u>38,563,216</u>									
Preferred: <u>1,000</u>									

Example: A company with a fiscal year end of December 31st, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2021 through December 31, 2022 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: x (If yes, you must complete the table below) **-SEE TABLE BELOW-**

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount At issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms	Holder	Control Person	Reason
4/4/14	4,320	8,500	-	4/4/2014	0.0001	Bright Star International	Kevin Dills	Working Capital
11/25/16	2,000	2,000	-	11/25/2017	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/20/17	-	2,700	-	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/3/17	3,000	3,000	-	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/12/17	1,100	1,100	-	4/12/2018	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/5/17	30,000	30,000	-	5/5/2018	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/9/17	12,000	12,000	-	5/9/2018	0.0001	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
9/14/17	4,000	4,000	-	9/14/2018	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
10/30/17	3,500	3,500	-	10/30/2018	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/5/18	6,000	6,000	-	1/5/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/18/18	1,000	1,000	-	1/18/2019	0.0001	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/5/18	3,000	3,000	-	3/5/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/23/18	1,900	2,500	-	3/23/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/20/18	3,500	3,500	-	4/20/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/18/18	5,500	5,500	-	5/18/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
7/20/18	1,500	1,500	-	7/20/2019	0.0080	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
8/6/18	300	1,100	-	8/6/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
8/31/18	1,400	1,400	-	8/31/2019	0.0090	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
11/15/18	3,250	3,250	-	11/15/2019	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/1/19	3,500	3,500	-	1/1/2020	0.0007	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/15/19	1,100	1,100	-	1/15/2020	0.0007	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
1/23/19	4,200	4,200	-	1/23/2020	0.0050	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
2/8/19	1,750	1,750	-	2/8/2020	0.0007	Chester W. Mason	Chester W. Mason	Working Capital
3/1/19	2,500	2,500	-	On Demand	0.0050	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/6/19	3,500	3,500	-	On Demand	0.0050	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/6/19	3,000	3,000	-	4/5/2020	0.0007	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
6/25/19	1,050	1,050	-	6/24/2020	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
10/31/19	4,300	4,300	-	4/30/2020	0.0007	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
11/1/19	1,300	1,300	-	On Demand	0.0050	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
12/31/19	2,100	2,100	-	6/30/2020	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/11/20	3,500	3,500	-	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/27/20	1,600	1,600	-	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/6/2020	600	600	99	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/15/2020	3,750	3,750	610	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/30/2020	2,000	2,000	321	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/21/2020	2,000	2,000	314	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/29/2020	1,250	1,250	194	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
6/30/2020	2,350	2,500	353	On Demand	0.0010	Charles Wagner	Charles Wagner	Working Capital
7/20/2020	6,000	6,000	882	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
7/28/2020	5,500	5,500	801	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
7/28/2020	2,500	2,500	364	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
8/6/2020	10,000	10,000	1,442	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
9/8/20	6,000	6,000	832	On Demand	0.0010	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
9/15/20	750	750	103	On Demand	0.0015	Charles Wagner	Charles Wagner	Working Capital
9/22/20	450	450	61	On Demand	0.0015	Charles Wagner	Charles Wagner	Working Capital
10/19/20	4,000	4,000	528	On Demand	0.5100	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
10/20/20	3,000	3,000	396	On Demand	0.4200	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
11/19/20	800	800	102	On Demand	0.3500	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
12/4/20	2,000	2,000	229	On Demand	0.4700	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
2/1/21	1,000	1,000	115	On Demand	None	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
2/12/21	15,500	15,500	1,750	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
2/18/21	5,000	5,000	560	On Demand	None	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
3/24/21	40,000	40,000	4,254	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
4/14/21	60,000	60,000	12,348	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
5/18/21	5,000	5,000	973	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
6/30/21	5,000	5,000	902	On Demand	5.0000	Life Sciences Journeys, Inc.	Kevin Dills	Working Capital
8/18/21	55,000	55,000	9,041	On Demand	4.0000	Bright Star International	Kevin Dills	Working Capital
9/1/21	255,000	255,000	39,570	On Demand	3.0000	Bright Star International	Kevin Dills	Working Capital
12/29/21	35,000	35,000	4,223	On Demand	1.0000	Bright Star International	Kevin Dills	Working Capital
2/14/22	5,000	5,000	526	On Demand	1.0000	Bright Star International	Kevin Dills	Working Capital
3/25/22	5,000	5,000	462	On Demand	1.0000	Bright Star International	Kevin Dills	Working Capital
4/4/22	20,000	20,000	1,782	4/4/2023	1.0000	Bright Star International	Kevin Dills	Working Capital
4/15/22	6,000	6,000	513	4/15/2023	1.0000	Bright Star International	Kevin Dills	Working Capital
6/16/22	1,500	1,500	98	6/16/2023	0.5000	Bright Star International	Kevin Dills	Working Capital
7/20/22	2,000	2,000	108	7/20/2023	0.5000	Bright Star International	Kevin Dills	Working Capital
8/3/22	3,000	3,000	148	8/3/2023	0.4000	Bright Star International	Kevin Dills	Working Capital
9/13/22	5,000	5,000	179	9/13/2023	0.3000	Bright Star International	Kevin Dills	Working Capital
9/26/22	75,000	75,000	2,367	9/26/2023	0.2000	Bright Star International	Kevin Dills	Working Capital
10/27/22	5,000	5,000	107	On Demand	0.3200	Bright Star International	Kevin Dills	Working Capital

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.
(Please ensure that these descriptions are updated on the Company's Profile on www.otcmarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The licensing, development, manufacturing, and commercialization of therapeutic drugs and medical devices with research conducted by licensors.

B. List any subsidiaries, parent company, or affiliated companies.

None

C. Describe the issuers' principal products or services.

Research, development, and commercialization of therapeutic drugs and medical devices designed for treatment of many types of cancers.

5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Licensing agreements providing for revenue generation from sale of drugs or medical devices in exchange for funding of R&D efforts of licensors. Upfront and ongoing payments to licensors as well as future royalties during the term of the agreements usually lasting through the period of exclusivity of patent rights for the intellectual property.

6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuer's securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Charles Wagner</u>	Board Chairman, Director	<u>San Francisco, CA</u>	<u>10,600,004</u> 4	<u>Common</u> Common	<u>27.487</u>	_____
<u>George Malasek</u>	<u>CEO</u>	<u>Frisco, TX</u>	<u>515,001</u>	<u>Common</u>	<u>1.335</u>	_____
<u>Carlos Barnett</u>	<u>Director</u>	<u>Carlsbad, CA</u>	<u>2,602,500</u>	<u>Common</u>	<u>6.749</u>	_____
<u>Shawn Crouse</u>	<u>Director</u>	<u>Corte Madera, CA</u>	<u>2,603,500</u>	<u>Common</u>	<u>6.751</u>	_____
<u>Stefan Gruenwald</u>	<u>Director</u>	<u>Encinitas, CA</u>	<u>2,586,000</u>	<u>Common</u>	<u>6.706</u>	_____

7) Legal/Disciplinary History

A. Identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties

thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Dimitrios Theofilopoulos
Address 1: Theo Law Firm
Address 2: 4225 Executive Square, Ste 600, La Jolla, CA 92037
Phone: (213) 359-3179
Email: dimitri@thelawfirm.com

Accountant or Auditor

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

Twitter: _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other] _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement.** This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: James B Smith
Firm: James B Smith, CPA, P.C.
Nature of Services: Accounting
Address 1: 17806 IH 10 West, Suite 300
Address 2: San Antonio, TX 78257

Phone: (210) 819-7304
Email: jim@jamesbsmithcpa.com

9) Financial Statements

A. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

B. The following financial statements were prepared by (name of individual)²:

Name: **James B Smith**
Title: **CPA**
Relationship to Issuer: **Consultant**

Describe the qualifications of the person or persons who prepared the financial statements: **CPA-TX**

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

SEE FINANCIAL STATEMENTS ATTACHED TO THIS DISCLOSURE DOCUMENT.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, George Malasek certify that:

1. I have reviewed this Disclosure Statement for Oncology Pharma, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under

² The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

2/14/2023 [Date]

/s/ George Malasek

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, George Malasek certify that:

1. I have reviewed this Disclosure Statement for Oncology Pharma, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

2/15/2023 [Date]

/s/ George Malasek

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

FINANCIAL STATEMENTS FOR THE PERIOD ENDING 12/31/2022

Oncology Pharma, Inc.
Balance Sheets
(Unaudited)

	<u>As of</u> <u>December 31, 2022</u>	<u>As of</u> <u>March 31, 2022</u>
ASSETS		
CURRENT ASSETS		
Cash	\$ 398	\$ 3,964
Total Current Assets	<u>398</u>	<u>3,964</u>
INVESTMENTS		
Investment in NanoSmart Pharmaceuticals, Inc. Licensing Agreement	351,350	351,350
Investment in KCL Therapeutics, Inc. Licensing Agreement	1,400,000	1,400,000
Investment in Regen Biopharma, Inc. Licensing Agreement	55,000	55,000
Investment in Sybleu, Inc. Licensing Agreement	237,250	237,250
Investment in Ribera Solutions, LLC Licensing Agreement	<u>95,000</u>	<u>75,000</u>
Total Investments	2,138,600	2,118,600
TOTAL ASSETS	<u>\$ 2,138,998</u>	<u>\$ 2,122,564</u>
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Accounts Payable and Accrued Expenses	\$ 261,088	\$ 213,387
Loans Payable Related Party	-	944
Convertible Notes Payable Related Party	3,550	3,550
Promissory & Convertible Notes Payable	<u>774,070</u>	<u>657,590</u>
Total Current Liabilities	1,038,708	875,471
TOTAL LIABILITIES	\$ 1,038,708	\$ 875,471
STOCKHOLDERS' EQUITY ((DEFICIT)		
Preferred Series A stock, \$0.001 par value, 100,000,000 shares authorized, 1 share issued and outstanding at September 30, 2022 and March 31, 2022	1,000	1,000
Common stock, \$0.001 par value, 900,000,000 shares authorized, 37,963,216 and 33,763,216 issued and outstanding at September 30, 2022 and March 31, 2022	193,694	188,894
Additional Paid In Capital	278,602,446	273,156,247
Retained Deficit	<u>(277,696,850)</u>	<u>(272,099,047)</u>
Total Stockholders' Equity (Deficit)	1,100,290	1,247,093
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	<u>\$ 2,138,998</u>	<u>\$ 2,122,564</u>

The accompanying Notes are an integral part of these financial statements

Oncology Pharma, Inc.
Statements of Operation
(Unaudited)

	<u>For the Nine Months Ended December 31, 2022</u>	<u>For the Nine Months Ended December 31, 2021</u>
Revenues	\$ -	\$ -
Costs and Expenses		-
General and Administrative	<u>100,122</u>	<u>51,161</u>
Total Operating Expenses	<u>100,122</u>	<u>51,161</u>
Operating Loss	(100,122)	(51,161)
Other Income and Expenses		
Gain from license fee settlement		54,167
Interest Expense	(5,497,681)	(104,604,788)
Loss from Abandonment of Mining Claims and Licenses	-	-
Total Other Income and Expenses	<u>(5,497,681)</u>	<u>(104,550,621)</u>
Net Loss Before Taxes	(5,597,803)	(104,601,782)
Income Taxes	-	
Net Loss	<u>\$ (5,597,803)</u>	<u>\$ (104,601,782)</u>
Net Loss Per Common Share (Basic and Diluted)	\$ (0.146)	\$ (3.42)
Weighted Average Common Shares Outstanding (Basic and Diluted)	38,263,216	30,550,716

The accompanying Notes are an integral part of these financial statements

Oncology Pharma, Inc.
Statements of Cash Flow
(Unaudited)

	<u>For the Nine Months Ended</u> <u>December 31, 2022</u>	<u>For the Nine Months Ended</u> <u>December 31, 2021</u>
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$ (5,597,803)	\$ (104,601,782)
Adjustments to reconcile net loss to cash used in operating activities		
Depreciation	-	
Gain from legal settlement		(54,167)
Issuance of common stock for services		
Issuance of common stock for interest expense	5,446,200	104,691,600
Changes in operating assets and liabilities		
Accounts payable and accrued expenses	47,701	(79,852)
Loans and notes payable	115,536	412,851
Loss from abandonment of mining claims and licenses	-	-
NET CASH (USED) PROVIDED IN OPERATING ACTIVITIES	<u>11,634</u>	<u>368,650</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Investment in Licensing Agreements	(20,000)	(1,755,000)
NET CASH (USED) PROVIDED FROM INVESTING ACTIVITIES	<u>(20,000)</u>	<u>(1,755,000)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Common stock to be issued for license agreements		
Common stock issued for license agreements		1,400,000
Increase in related party debt		-
Conversion of notes payable to common stock	4,800	6,400
Stock option grant for license agreement		
Issuance of Convertible Notes Payable		-
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES	<u>4,800</u>	<u>1,406,400</u>
NET CHANGE IN CASH	(3,566)	20,050
CASH AT BEGINNING OF PERIOD	<u>3,964</u>	<u>8,954</u>
CASH AT END OF PERIOD	\$ 398	\$ 29,004
SUPPLEMENTARY INFORMATION		
Stock issued for debt	\$ 4,800	\$ 6,400

The accompanying Notes are an integral part of these financial statements

Statements of Changes in Stockholder's Deficit
For the Nine Months Ended December 31, 2022 and 2021

	Common Stock		Preferred Stock		Additional Paid-in-Capital	Accumulated Deficit	Total
	Shares	Amount	Shares	Amount			
Balance as at March 31, 2021	<u>27,338,216</u>	<u>\$ 182,469</u>	<u>1,000</u>	<u>\$ 1,000</u>	<u>\$ 167,118,838</u>	<u>\$ (167,472,319)</u>	<u>\$ (170,012)</u>
Shares issued for licensing rights	50,000	50			1,399,950		1,400,000
Shares issued for debt conversion	6,400,000	6,400			104,691,600		104,698,000
Shares cancelled in legal settlement	(25,000)	(25)			(54,142)		(54,167)
Net Income (Loss) for period ending December 31, 2021						(104,601,783)	(104,601,783)
Balance as at December 31, 2021	<u>33,763,216</u>	<u>\$ 188,894</u>	<u>1,000</u>	<u>\$ 1,000</u>	<u>\$ 273,156,246</u>	<u>\$ (272,074,102)</u>	<u>\$ 1,272,038</u>
<hr/>							
Balance as at March 31, 2022	<u>33,763,216</u>	<u>\$ 188,894</u>	<u>1,000</u>	<u>\$ 1,000</u>	<u>\$ 273,156,246</u>	<u>\$ (272,099,047)</u>	<u>\$ 1,247,093</u>
Shares issued for debt conversion	4,800,000	4,800			5,446,200		5,451,000
Net Income (Loss) for period ending December 31, 2022						(5,597,803)	(5,597,803)
Balance as at December 31, 2022	<u>38,563,216</u>	<u>\$ 193,694</u>	<u>1,000</u>	<u>\$ 1,000</u>	<u>\$ 278,602,446</u>	<u>\$ (277,696,850)</u>	<u>1,100,290</u>

The accompanying Notes are an integral part to these financial statements.

ONCOLOGY PHARMA, INC.

Notes to Financial Statements for the Nine Months Ended December 31, 2022

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Oncology Pharma, Inc., (the “Company”) (formerly SourcingLink.net, Inc.) was incorporated in 1993 and is engaged in the development, manufacturing and commercialization of therapeutics. The Company is a Nevada corporation.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a March 31 year-end.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

E. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, "Income Taxes." Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company follows ASC Topic 740 for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change.

F. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

G. REVENUE RECOGNITION

Revenue will be recognized when persuasive evidence of an arrangement exists, pricing is fixed and determinable, collection is reasonably assured and delivery or performance of service has occurred. Customer prepayments are reflected as deferred revenue as long as there is persuasive evidence that the purchased product will be shipped within a reasonable time. Sales revenue will be recognized upon the completion of provided professional services or the shipment of merchandise to customers.

F. STOCK-BASED COMPENSATION

The Company recognizes share-based compensation, including stock option grants, warrants and restricted stock grants at their fair value on the grant date. Share based payment awards issued to non-employees for services rendered will be recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable. Compensation expense is generally recognized on a straight-line basis over the vesting period.

NOTE 2 . RECENT ACCOUNTING PRONOUNCEMENTS

The Company has evaluated the recent accounting pronouncements through December 31, 2022 and believes that none of them will have a material impact on the Company's Financial Statements.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated an accumulated deficit of \$277,696,850

as of December 31, 2022. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company is taking steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) raising equity financing; 2) developing the business model to generate sales.

NOTE 4. CONVERTIBLE AND PROMISSORY NOTES PAYABLE

As of December 31, 2022, the Company was party to Convertible Notes Payable (Exclusive of Convertible Notes Payable to Related Party) of \$768,070 convertible into the common shares of the Company. On March 31, 2020 both of Bright Star International, Inc. ("BSI") and Life Sciences Journeys, Inc. ("LSJ") have agreed to forgive all accrued interest due but unpaid on all convertible notes held by Bright Star International, Inc. and Life Sciences Journeys, Inc. as of March 31, 2020 ("Fiscal Year End Notes"). Bright Star International, Inc. and Life Sciences Journeys, Inc. have agreed that no further interest shall accrue on the Convertible Notes issued prior to April 1, 2020. During the fourth quarter of the year ended March 31, 2021, the Company also issued promissory notes with no conversion rights in the amount of \$6,000 as described below. Total Notes Payable at December 31, 2022 was \$774,070.

<u>Date of Note Issuance</u>	<u>Outstanding Balance (\$)</u>	<u>Holder</u>
<u>Convertible Notes:</u>		
4/4/2014	\$ 4,320	BSI
11/25/2016	\$ 2,000	LSJ
4/3/2017	\$ 3,000	LSJ
4/12/2017	\$ 1,100	LSJ
5/5/2017	\$ 30,000	LSJ
5/9/2017	\$ 12,000	LSJ
9/14/2017	\$ 4,000	LSJ
10/30/2017	\$ 3,500	LSJ
1/5/2018	\$ 6,000	LSJ
1/18/2018	\$ 1,000	LSJ
3/5/2018	\$ 3,000	LSJ
3/2/3 2018	\$ 2,500	LSJ
4/20/2018	\$ 3,500	LSJ
5/18/2018	\$ 5,500	LSJ
7/20/2018	\$ 1,500	LSJ
8/6/2018	\$ 300	LSJ
8/31/2018	\$ 1,400	LSJ
11/15/2018	\$ 3,250	LSJ
1/1/2019	\$ 3,500	LSJ
1/15/2019	\$ 1,100	LSJ
1/23/2019	\$ 4,200	LSJ
2/8/2019	\$ 1,750	Chester W. Mason

3/6/2019	\$ 2,500	LSJ
3/6/2019	\$ 3,500	LSJ
4/6/2019	\$ 3,000	LSJ
6/25/2019	\$ 1,050	LSJ
10/31/2019	\$ 4,300	LSJ
11/1/2019	\$ 1,300	LSJ
12/31/2019	\$ 2,100	LSJ
3/11/2020	\$ 3,500	LSJ
3/27/2020	\$ 1,600	LSJ
4/6/2020	\$ 600	LSJ
4/14/2020	\$ 3,750	LSJ
4/30/2020	\$ 2,000	LSJ
5/21/2020	\$ 2,000	LSJ
5/29/2020	\$ 1,250	LSJ
7/20/2020	\$ 6,000	LSJ
7/28/2020	\$ 5,500	LSJ
7/28/2020	\$ 2,500	LSJ
8/6/2020	\$ 10,000	LSJ
9/8/2020	\$ 6,000	LSJ
10/19/2020	\$ 4,000	LSJ
10/20/2020	\$ 3,000	LSJ
11/19/2020	\$ 800	LSJ
12/4/2020	\$ 2,000	LSJ
2/12/2021	\$ 15,500	LSJ
4/14/2021	\$ 60,000	LSJ
5/18/2021	\$ 5,000	LSJ
6/30/2021	\$ 5,000	LSJ
8/18/2021	\$ 55,000	BSI
9/1/2021	\$ 255,000	BSI
12/29/2021	\$ 35,000	BSI
2/14/2022	\$ 5,000	BSI
3/25/2022	\$ 5,000	BSI
4/4/2022	\$ 20,000	BSI
4/15/2022	\$ 6,000	BSI
6/16/2022	\$ 1,500	BSI
7/20/2022	\$ 2,000	BSI
8/3/2022	\$ 3,000	BSI
9/13/2022	\$ 5,000	BSI
9/26/2022	\$ 75,000	BSI
10/27/22	<u>\$ 5,000</u>	BSI
Total Convertible Notes	\$ 768,070	

Promissory Notes:

2/1/2021	\$ 1,000	LSJ
2/12/2021	\$ <u>5,000</u>	LSJ
Total Promissory Notes	\$ 6,000	

Total Convertible and
Promissory Notes \$774,070

NOTE 5. RELATED PARTY TRANSACTIONS

As of December 31, 2022, the Company is indebted to related parties (Charles Wagner, Chairman) in the amount of \$3,550 as convertible debt. The debt consists of cash advanced by Mr. Wagner to the Company to fund operations.

On June 30, 2020, the Company issued a convertible note to Charles Wagner. in the principal amount of \$2,500 and which has an outstanding balance of \$2,350 at December 31, 2020. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.001 per share.

On September 15, 2020, the Company issued a convertible note to Charles Wagner. in the principal amount of \$750. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.0015 per share.

On September 22, 2020, the Company issued a convertible note to Charles Wagner. in the principal amount of \$450. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.0015 per share.

NOTE 6. STOCKHOLDER'S EQUITY

On October 9, 2020, the Company implemented a decrease in common shares by a 1 for 100 reverse split. The financial statements presented reflect the decrease in shares resulting from the reverse split for the relevant periods shown.

The stockholders' equity section of the Company contains the following classes of capital stock as of December 31, 2022:

Preferred Stock, \$0.001 Par Value
100,000,000 Shares Authorized
1 Share Issued

Common Stock, \$0.001 Par Value

900,000,000 Shares Authorized

38,563,216 Shares Issued

NOTE 7. SUBSEQUENT EVENTS.

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation, no material events have occurred that require disclosure.